Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UnitedHealth drops Nexium

This article was originally published in The Tan Sheet

Executive Summary

Astra-Zeneca's proton pump inhibitor Nexium (esomeprazole) was dropped from some UnitedHealth Group plans Sept. 1 and will be let go from others later this year, the firm says. The cost-sensitive measure reflects the lower-cost availability of Nexium predecessor Prilosec OTC (omeprazole), which AZ co-markets with Procter & Gamble. AZ is disappointed with the decision, saying it is not good for patients and overrides the better judgment of healthcare professionals, according to a spokesperson. The firm is not revising Nexium revenue projections. In recent years, other payors have chosen to remove Nexium and other PPIs from formularies, or to provide coverage for Prilosec OTC (1"The Tan Sheet" May 16, 2005, p. 11)...

You may also be interested in...

OTC Impact: DoD Nexium Formulary Move Could Preface Future Cost-Cutting

The Defense Department's decision to cease pharmacy benefit coverage of AstraZeneca's Nexium could pave the way for similar cost-cutting measures in other federal employee health plans

Faster, Better? Fujitsu, Polarisqb 'Quantum-Inspired' Tech Speeds Discovery

Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.

Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts